<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344667</url>
  </required_header>
  <id_info>
    <org_study_id>RD-157</org_study_id>
    <nct_id>NCT02344667</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT</brief_title>
  <official_title>Randomized Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. Volume Modulated Arc Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juravinski Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juravinski Cancer Centre Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Juravinski Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies support the use of Stereotactic Body Radiation Therapy (SBRT) for the&#xD;
      treatment of localized prostate cancer (PrCa). SBRT is a way to deliver radiation very&#xD;
      precisely allowing higher doses to be delivered with fewer treatments, potentially improving&#xD;
      patient outcomes. Cyberknife and Volume Modulated Arc Therapy (VMAT) are accepted SBRT&#xD;
      techniques. However, the effects of the specific SBRT treatment technique on patient outcomes&#xD;
      have not been evaluated in randomized trials.&#xD;
&#xD;
      Although such a trial would be of great interest, patients' willingness to participate is&#xD;
      unclear. Multiple patient and clinician factors contribute to the decision to enter a&#xD;
      randomized trial. This feasibility study will evaluate patients' willingness to participate&#xD;
      in a trial comparing Cyberknife and VMAT SBRT for the treatment of early stage PrCa. Patients&#xD;
      accepting enrolment will be randomized to one of the two types of SBRT delivery. Up to 66&#xD;
      patients will be approached, and up to 40 randomized. A questionnaire will help to identify&#xD;
      the factors influencing the patient's decision to participate or not. This study will gather&#xD;
      information on feasibility, PSA control, patient outcomes and side effects, and will inform&#xD;
      the design of a future randomized phase II/III study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient acceptability of a randomized trial comparing Cyberknife and Volume Modulated Arc Therapy (VMAT) based SBRT techniques for the treatment of localized prostate cancer as measured by number of patients willing to participate in randomized trial.</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cyberknife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyberknife based SBRT 36.25 Gy in 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volume Modulated Arc Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
    <arm_group_label>Volume Modulated Arc Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
          -  Histological evaluation of prostate biopsy with assignment of a Gleason score to the&#xD;
             biopsy material; Gleason scores ≤ 7&#xD;
&#xD;
          -  Clinical stage T1-2b (AJCC 7th edition)&#xD;
&#xD;
          -  PSA ≤ 10 ng/mL. PSA should not be obtained within 10 days after prostate biopsy.&#xD;
&#xD;
          -  ECOG Performance Status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or&#xD;
             lymphomatous/hematogenous malignancy unless continually disease free for a minimum of&#xD;
             5 years.&#xD;
&#xD;
          -  Evidence of distant metastases&#xD;
&#xD;
          -  Regional lymph node involvement&#xD;
&#xD;
          -  Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer.&#xD;
             Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy&#xD;
&#xD;
          -  Previous hormonal therapy, such as LHRH agonists or LHRH antagonists, anti-androgens,&#xD;
             estrogens, or surgical castration&#xD;
&#xD;
          -  Use of finasteride or dutasteride within 30 days prior to registration. PSA should not&#xD;
             be obtained prior to 30 days after stopping finasteride or dutasteride.&#xD;
&#xD;
          -  Previous or concurrent cytotoxic chemotherapy for prostate cancer&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Patient unable to provide study-specific informed consent&#xD;
&#xD;
          -  Inability to complete the Expanded Prostate Cancer Index Composite (EPIC)&#xD;
             questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joanna Laba, MD</last_name>
    <phone>905-387-9495</phone>
    <phone_ext>64702</phone_ext>
    <email>labaj@hhsc.ca</email>
  </overall_contact>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>January 18, 2015</last_update_submitted>
  <last_update_submitted_qc>January 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Juravinski Cancer Center</investigator_affiliation>
    <investigator_full_name>Dr. Himu Lukka</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

